GSK plc Q2 FY26 Earnings Analysis

- GSK expects another year of profitable growth in 2026, confirmed in their guidance. - Specialty Medicines sales grew 14% in Q1 and continue to drive overall growth. - Vaccines, notably Shingrix, contributed significantly with a 20% sales increase in Q1; however, tougher comparators expected later this year in Europe and Japan. - New product launches like Nucala COPD, Exdensur, and Blenrep show strong momentum and growth potential. - Pipeline acceleration and BD activities focus on high-potential assets, including COPD, oncology ADCs, and Efimosfermin in MASH. - HIV portfolio growth continues with a 10% sales increase in Q1 alongside advancements in long-acting regimens. - Jemperli is on track to reach the £2 billion revenue potential in oncology with upcoming trial results expected to further support growth. - Inventory stocking effects (e.g., Shingrix) may moderate but underlying demand remains stable or improving in key markets like China and the U.S.

- GSK expects another year of profitable growth, with guidance confirmed during the Q1 2026 results call. - Core operating profit grew 10% in Q1, reflecting strong sales and improved product mix. - Earnings per share (EPS) increased by 9% in Q1, supported by higher operating profit and share buybacks. - Cash generation was strong at GBP 1.4 billion, supporting capital allocation priorities. - Operating profit growth is expected to be predominantly weighted towards the second half of the year, factoring in productivity benefits and prior year comparators. - Continued investment in R&D and pipeline acceleration aims to drive future top-line growth and commercial success. - The company is committed to accelerating late-stage pipeline assets and lifecycle management to enhance growth prospects and shareholder value.

- Investments in business development (BD) primarily included a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics. - In Q2, an expected outflow of $950 million for the acquisition of 35Pharma, whose lead asset HS235 is in Phase I development for pulmonary hypertension. - Portfolio optimization actions such as the divestment of the Rockville manufacturing site and the out-licensing of linerixibat contributed to capital generation. - Strategic acquisitions in Q1 included ozureprubart (for food allergies) and HS235 (pulmonary hypertension), both aiming to be best-in-class assets. - Planning to reinvest cash income from strategic actions and strong cash generation into pipeline acceleration and growth initiatives. - Share buyback continued on track and shareholder returns totaled over GBP 0.9 billion. - Overall, capital deployment focused on disciplined BD, accelerating late-stage pipeline, and productivity improvements.

- No explicit mention of new fundraising through debt or equity in the provided excerpts. - Company is focused on strong cash generation and capital allocation priorities with net debt at 1.4x EBITDA. - Recent investments include a GBP 1.4 billion upfront payment to acquire Rapt Therapeutics. - Share buyback program is ongoing and on track for completion at half year. - Upcoming outflow of $950 million expected for acquisition of 35Pharma in Q2. - Portfolio optimization actions (special dividend, site divestments, out-licensing) are planned to positively impact net debt by $1.2 billion in H1. - No mention of issuing new equity or additional debt for fundraising within reported periods.

- U.S. Shingrix inventory stocking is around 45%, up 3.5 percentage points versus the same time last year, within the typical annual increase range of 2-4 percentage points. - Wholesaler stocking in Q1 2026 was 0.6 million doses, steady compared to 0.5 million at the end of last year and 0.4 million during the same time last year. - Retail inventory increased to 2.4 million doses compared to 1.7 million at the same time last year, partly due to the launch of the prefilled syringe (PFS). - China demand is improving with an increase in doses administered; however, sales numbers do not yet reflect this due to stock being drawn down from GSK’s inventory. - Stocking and inventory build reflect a balance of supply readiness and underlying patient demand, particularly focused on the comorbid population.